Literature DB >> 15793872

Age scope of high-risk population for esophageal cancer in Ci county.

Zhi-Feng Chen1, Jun Hou, Zhen-Wei Ding, Cui-Lan Guo, Cui-Yun Qiao, Guo-Hui Song, Shao-Sen Li, Jian-Hui Zhang, Yu-Tong He.   

Abstract

AIM: To define the age scope of high-risk population for esophageal cancer (EC) in Ci county.
METHODS: The results of endoscopic examination of 2 013 subjects, cytological screening of 16 763 persons and records of 9 265 patients with EC were analyzed by Ridit methods, the standard age group was 45-49 year group.
RESULTS: The average age of patients with moderate esophageal epithelium dysplasia by endoscopic examination was 53.5 years, of severe esophageal epithelium dysplasia, 51.4 years, early EC, 55.6 years. The average age of stage one severe epithelium dysplasia (SEEDI) by cytological screening was 51.2 years, of stage two severe epithelium esophageal dysplasia (SEED II) 51.6 years, of advanced EC 61.7 years. In the group of 40-year olds, the value of Ridit by pathological diagnosis was 0.46, 95% CI, 0.45-0.47, that by cytological diagnosis was 0.45, 95% CI, 0.43-0.47. As the age increased at five-year intervals, the value of Ridit increased significantly.
CONCLUSION: In Ci county of a high incidence area of EC, the age definition of high-risk population should be above 45 years.

Entities:  

Mesh:

Year:  2005        PMID: 15793872      PMCID: PMC4305882          DOI: 10.3748/wjg.v11.i12.1818

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  10 in total

1.  [Analyses of variation trend and short-term detection of Chinese malignant tumor mortality during twenty years].

Authors:  L Li; F Lu; S Zhang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1997-01

Review 2.  Comprehensive prevention and treatment for esophageal cancer.

Authors:  S Lu; P Lin; G Wang; X Luo; M Wu
Journal:  Chin Med J (Engl)       Date:  1999-10       Impact factor: 2.628

3.  An analysis of esophageal cancer incidence in Cixian county from 1974 to 1996.

Authors:  Yu-Tong He; Jun Hou; Cui-Yun Qiao; Zhi-Feng Chen; Guo-Hui Song; Shao-Sen Li; Fan-Shu Meng; Hong-Xin Jin; Chao Chen
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

4.  Cancer statistics, 2001.

Authors:  R T Greenlee; M B Hill-Harmon; T Murray; M Thun
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

5.  Cytologic screening for esophageal cancer in a high-risk population in Anyang County, China.

Authors:  Huihua Yang; Aasmund Berner; Qiang Mei; Karl-Erik Giercksky; Trond Warloe; Guanrui Yang; Jianguo Cui; Zhenhe Suo; Sanshen Zhang; Jahn M Nesland
Journal:  Acta Cytol       Date:  2002 May-Jun       Impact factor: 2.319

6.  [Long-term effect of treating patients with precancerous lesions of the esophagus].

Authors:  Z Ding; F Gao; P Lin
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1999-07

7.  [Significance of screening by iodine staining of endoscopic examination in the area of high incidence of esophageal carcinoma].

Authors:  Gui-Qi Wang; Wen-Qiang Wei; Ning Lu; Chang-Qing Hao; Dong-Mei Lin; Hong-Tu Zhang; Yun-Tian Sun; You-Lin Qiao; Guo-Qing Wang; Zhi-Wei Dong
Journal:  Ai Zheng       Date:  2003-02

8.  Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden.

Authors:  Brenda K Edwards; Holly L Howe; Lynn A G Ries; Michael J Thun; Harry M Rosenberg; Rosemary Yancik; Phyllis A Wingo; Ahmedin Jemal; Ellen G Feigal
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

Review 9.  Endoscopic diagnosis and surveillance of Barrett's esophagus.

Authors:  M Brian Fennerty
Journal:  Gastrointest Endosc Clin N Am       Date:  2003-04

10.  Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.

Authors:  John M Inadomi; Richard Sampliner; Jesper Lagergren; David Lieberman; A Mark Fendrick; Nimish Vakil
Journal:  Ann Intern Med       Date:  2003-02-04       Impact factor: 25.391

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.